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ABSTRACT 
The transforming growth factor-β (TGF-β) system signals via protein kinase receptors and Smad 
mediators to regulate a plethora of biological processes, including morphogenesis, embryonic 
development, adult stem cells differentiation, immune regulation, wound healing or 
inflammation. In addition, alterations of specific component of the TGF-β signaling pathway 
may contribute to a broad range of pathologies such as cancer, cardiovascular pathology, fibrosis 
or congenital diseases. The knowledge about the mechanisms involved in TGF-β signal 
transduction has allowed a better understanding of the disease pathogenicity as well as the 
identification of several molecular targets with great potential in therapeutic interventions. 
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INTRODUCTION 
Since the discovery of the first member of the TGF-β superfamily in the early 1980´s, a steadily 
growing number of related members have been identified and functionally characterized in 
vertebrates and invertebrates. In mammals, the TGF-β family regulates many cellular functions 
including cell growth, differentiation, adhesion, migration, and apoptosis. TGF-β signalling is 
also essential for embryonic development, including germ-layer specification and patterning. 
Alterations of the TGF-β signaling pathway are involved in human diseases such as 
cardiovascular, fibrosis, reproductive, cancer or wound-healing disorders. Some of these diseases 
are hereditary conditions such as hereditary haemorrhagic telangiectasia, familial primary 
pulmonary hypertension or juvenile polyposis. 
Here, first we will review the process of intracellular signal transduction from the soluble factors 
to the membrane-bound receptors and downstream into the nucleus. This pathway is relatively 
simple and well conserved in evolution. We will briefly describe the molecular components that 
make up the core pathway: ligands, receptors and SMADs. Second, we will describe the role of 
TGF-β signaling in the normal physiology and how its malfunction results in diseases affecting 
different organs, including, among others, cardiovascular system, pulmonary, bone, muscle and 
reproductive disorders or cancer. Finally, we will summarize the current knowledge about the 
therapeutic approaches that target different components of the TGF-β signaling pathway. The use 
of antibodies, antisense oligonucleotides, soluble receptors, recombinant ligands or chemical 
kinase inhibitors in preclinical and clinical studies will be discussed. To conclude, we will take a 
look at future challenges in the field. 
1. The TGF-β signaling pathway. The transforming growth factor beta (TGF-β) system 
includes several components involved at different levels of a standard outside-inside signaling 
pathway, namely, soluble factors, specific membrane receptors and intracellular mediators.  
1.1. Soluble factors of the TGF-β family proteins. The TGF-β family includes a large number 
of factors structurally and functionally related which act as multifunctional regulators of a wide 
range of biological processes. The members of TGF-β family are implicated, among others, in 
morphogenesis, embryonic development, adult stem cells differentiation, immune regulation, 
wound healing, inflammation and cancer. The first member of the family, TGF-β, was 
discovered in 1983 because of its ability to induce (‘transform’) the growth of cultured rat 
fibroblasts [1,2]. So far, more than 40 members of this family are known which cluster in several 
subfamilies, such as TGF-βs, bone morphogenetic proteins (BMPs), growth and differentiation 
factors (GDFs), activins, inhibins, Mullerian inhibitory factor (MIF) or Nodal (Figure 1). 
TGF-βs. Six distinct isoforms of TGF-β with a variable degree of homology have been 
discovered, although only TGF-β1, TGF-β2, and TGF-β3 isoforms are expressed in mammals 
[3,4] and their human genes are located on chromosomes 19q13, 1q41, and 14q24, respectively 
[5]. The three TGF-β1, TGF-β2, TGF-β3 proteins are synthesized as pro-peptide precursors with 
a signal domain, followed by the prodomain (also named latency associated peptide -LAP-) and 
the mature domain. The signal domain is removed in the endoplasmic reticulum, and then a 
cleavage by the convertase family of endoproteases occurs between LAP and the mature 
homodimer protein [6]. Then, LAP remains associated with the mature domain forming a small 
latent complex (SLC) until bioactive TGF-β is released. After secretion, SLC is covalently 
associated, through LAP, with latent TGF-β binding proteins (LTBPs), forming the large latent 
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complex (LLC), which also binds to the extracellular matrix (ECM) proteins, such as fibronectin 
and fibrillin. Although all members of TGF-β family are synthesized as precursor proteins 
containing LAP, the capacity of LAP to maintain the ligands in a latent form is not conserved 
among all family proteins [7]. 
BMPs. BMPs were originally identified as a family of proteins that induces the formation of 
bone and cartilage when implanted at ectopic sites in rats. Members of the BMP family have 
been found in vertebrates as well as in invertebrates and are known to exhibit a wide range of 
biological effects on various cell types [8]. BMPs regulate the transcription of several genes 
involved in osteogenesis, neurogenesis, and ventral mesoderm specification. Members of the 
BMP family can be classified into several subgroups, including BMP2/4 group, BMP5/6/7/8 
group, osteogenic protein-1 (OP-1) group, and BMP9/10 group [8]. Nodal (also known as 
BMP16) plays a critical role in early stages of development for cell fate determinations as well as 
in cell differentiation. Studies of the mouse Nodal gene suggest that it may be essential for 
mesoderm formation and subsequent organization of left-right axial structures in early 
embryonic development [9]. GDFs were discovered when searching for additional members of 
the TGF-β superfamily [10], and are classified within the BMPs family. So far, at least eleven 
components of GFDs have been described: GDF1-3, GDF5-11 and GDF15 [11].  
MIF. MIF, also known as anti-Müllerian hormone (AMH) has been mainly studied for its 
regulatory role in male sex differentiation. MIF is implicated in the regression of Müllerian ducts 
in male fetuses and in the development and function of gonads of both sexes [12,13]. 
Activins. Activins are structurally related proteins involved in the control of cell proliferation, 
differentiation, apoptosis, metabolism, homeostasis, differentiation, immune response, and 
endocrine function [14]. Activins are produced in the gonads, pituitary gland, placenta, and other 
organs. Activins enhance follicle-stimulating hormone (FSH) biosynthesis and secretion, and 
participates in the regulation of the menstrual cycle. Activins possess a cysteine knot scaffold 
and are secreted as homodimers or heterodimers of inhibin β-subunits. Although four β-subunit 
genes (βA, βB, βC, and βE) have been described in humans, only dimers composed of βA/βA 
(activin A), βB/βB (activin B), and βA/βB (activin AB) subunits have been shown to be 
biologically active [15] (Supplementary Figure 1). 
Inhibins. Inhibins were originally characterized as proteins produced by the gonads that act in an 
endocrine manner to negatively regulate FSH synthesis and secretion from the anterior pituitary. 
As such, inhibins are essential for normal reproductive and endocrine function [15]. Inhibins are 
closely related to activins. Inhibins are disulfide-linked heterodimers comprising an α-subunit 
and either a βA or βB subunit to form inhibin A and inhibin B, respectively (Supplementary 
Figure 1). 
1.2. The TGF-β Receptors. All TGF-β family members bind cell surface serine/threonine 
kinase receptors types I and II, which form heteromeric complexes in the presence of dimerized 
ligands. Seven type I TGF-β receptors, also named activin like-receptor kinase (ALKs), as well 
as five different type II TGF-β receptors have been described (Figure 2 and Table 1). In addition, 
TGF-β ligands may also interact with the co-receptors endoglin and betaglycan (known as type 
III TGF-β receptors), which modulate the receptor kinase transduction [16-18]. Soluble ligands 
bind first to the constitutively active type II receptor, followed by the interaction and 
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phosphorylation of a glycine/serine (GS) rich domain of the type I receptor to produce an 
activated ligand-receptor complex [19]. This phosphorylation of the type I receptor disrupts the 
interaction between the kinase domain and a TGF-β signaling inhibitor, FKBP12. In addition, the 
phosphorylation of the GS domain increases its acidic nature, allowing the interaction with the 
basic domain of the downstream effectors Smads, which are then, phosphorylated by type I 
receptors. Both types I and II kinase receptors are themselves phosphorylated in tyrosine residues 
as well as in serine/threonine residues, probably implicated in a cross-talk activity regulation of a 
plethora of signal transduction pathways. 
The activity of TGF-β kinase receptors can be also regulated by the type III receptors (TβRIII) 
endoglin or betaglycan [17,18]. Endoglin and betaglycan are type I integral membrane proteins 
with large extracellular domains, regular hydrophobic transmembrane domains, short 
cytoplasmic domains and lacking kinase signaling motifs. The ubiquitously betaglycan is a major 
TGF-β binding molecule at the cell surface that binds with high affinity several members in the 
TGF-β family, including TGF-β1, TGF-β2, TGF-β3, Activin-A, BMP2, BMP4, BMP7 and 
GDF5 [17]. Betaglycan interacts with, and presents ligand to, the type II TGF-β receptor. This 
presenting ability of betaglycan increases ligand binding to their respective cognate type I and 
type II TGF-β superfamily receptors to enhance their signaling. In addition, betaglycan 
stimulates BMP signaling by regulating the traffic and cell localization of interacting receptors 
[19]. However, betaglycan can inhibit both BMP and activin signaling, promoting the binding of 
inhibin to the corresponding type II signaling receptors [20]. At variance with betaglycan, 
endoglin is predominantly expressed in vascular endothelial cells, a cell type that has little or no 
betaglycan expression. Endoglin interacts with TGF-β1, ActivinA, BMP2 and BMP7, requiring 
the presence of the corresponding signaling receptors; by contrast, endoglin can bind directly 
TGF-β3 and BMP9 independently of the kinase receptors [18]. Endoglin enhances TGF-
β1/Smad2 and TGF-β1-, BMP7- and BMP9-dependent Smad1/5 responses, while inhibits TGF-
β/Smad3 pathways [17,18,21,22]. Endoglin and betaglycan belong to the zona pellucida (ZP) 
family of proteins characterized by the proteolytic cleavage of their extracellular domain [23,24]. 
Of note, the released soluble protein may act antagonizing the effects of the corresponding 
membrane-associated TβRIII [17,18] (Supplementary Figure 2). 
1.3. Smad family dependent signal transduction. Intracellular TGF-β signaling is mediated by 
the Smad family of proteins. Members of the Smad family are well conserved and can be 
classified in three groups: i) Receptor associated Smads (R-Smad); ii) Cooperating Smads (Co-
Smad); and iii) Inhibitory Smads (I-Smads) [25]. The activated receptor complexes transduce 
intracellular signaling by the type I receptor phosphorylation of the R-Smads in their carboxy-
terminal domains [16]. The unphosphorylated R-Smads are transcriptionally inactive and 
sequestered in the cytoplasm by specific retention proteins such as SARA (Smad anchor for 
receptor activation) [16] or endofin [8]. In humans, five different R-Smads have been described 
that are substrate for activated TGF-β receptors (Smad1, 2, 3, 5, and 8). Smad2 and Smad3 are 
substrate for TGF-β and activins, whereas Smad1, 5 and 8 are substrate for BMP, GDF and MIFs 
routes (Figure 2). Each R-Smad contains three distinct domains, two highly conserved domains 
at the N-terminus and the C-terminus, named MH1 and MH2, respectively and a linker domain. 
MH1 can interact with DNA and with other proteins and possesses a nuclear localization signal 
(NLS), while MH2 mediates homo- or hetero-oligomerization of the Smads and the 
transactivation of Smad nuclear complexes. The highly variable linker region is located between 
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MH1 and MH2 domains, is enriched in prolines and has potential serine/theronine substrates for 
phosphorylation [26]. Upon ligand activation of the TGF-β receptor complex, the type I receptor 
phosphorylates R-Smad at a serine rich C-terminal motif, and then the phosphoR-Smad 
associates with Smad4 (mammalian Co-Smad). Interestingly, Co-Smad lacks the C-terminal 
motif for type I receptor phosphorylation [15]. The activated Smad complex consists of a trimer 
of single Co-Smads and homo or hetero-dimers of R-Smads. This Smad complex is shuttled into 
the nucleus where, in collaboration with other transcription factors, binds and regulates 
promoters of different target genes [16]. Two of these genes are I-Smads, Smad6 and Smad7. 
The induced expression of these inhibitory Smads produces a negative-feedback regulation of the 
TGF-β signaling [27]. I-Smads contain a characteristic C-terminal MH2 domain, but they lack 
the conserved MH1 domain . Smad6 preferentially inhibits BMP signaling by disrupting the 
Smad1/Co-Smad interaction and forming an inactive Smad1/Smad6 complex. In addition, 
Smad7 inhibits R-Smad phosphorylation by binding the TGF-β, activin and BMP type I 
receptors [28]. Once in the nucleus, the phosphoR-Smad/Co-Smad complex can bind, through 
the MH1 domain, with weak affinity to Smad-binding elements (SBEs) in the DNA. Smad3 
recognizes a 5 base-pair -GTCTG-, whereas Smad4 and Smad1,-5 and 8 recognize non-
consensus GC-rich motifs. In Smad2, a 30 amino acid insertion in the MH1 domain disables its 
individual binding to DNA. The binding of Smad complexes to DNA is crucial for the 
transcriptional activation of Smad target genes, but requires additional interactions with other 
transcription factors to form a large transcriptional complex with high-affinity for chromatin 
[16,27,28]. 
Regarding the Smad mediators involved, TGF-β superfamily members are classified into TFG-
β/Nodal/Activin group and BMP/GDF group. TFG-β/Nodal/Activin signals are transduced 
through type I and type II receptors through R-Smad proteins Smad2 and Smad3, while 
BMP/GDF signals are transduced via type I and type II receptors through R-Smad proteins 
Smad1, Smad5 and Smad8 [16,27,28,25] (Figure 2). 
1.4. Regulation of the TGF-β pathway. All components of the TFG-β pathway are subjected to 
a fine tuning, at different levels, in the modulation of TGF-β superfamily signal transduction. 
TGF-βs are secreted and maintained as an inactive form in the LLC that binds to ECM proteins 
[7], and whose bioavailability depends on the activation of a proteolytic cleavage or integrin 
interaction. Unlike TGF-β, BMPs are secreted in their active form and their activity is regulated 
by BMP antagonists, proteins that bind directly to BMPs and prevent them from interacting with 
their respective type I and type II receptors. Based on the size of their cysteine knot, a common 
arrangement of six half cysteine residues that form three intra-chain disulphide bonds, the BMP 
antagonists can be classified in four subfamilies: i) Dan; ii) Chordin; iii) Twisted gastrulation; 
and iv) Noggin. These BMP antagonists have differential affinities for the different BMPs. 
Ligand access to, and signaling by, the kinase receptors can be modulated by several auxiliary 
receptors, including the TβRIII members endoglin and betaglycan, the repulsive guidance family 
of glycosylphosphatidylinositol-anchored proteins DRAGON, RGMa, and hemojuvelin, 
neuropilin, and the member of the α2-macroglobulin/C3, C4, C5 family of thioester containing 
proteins, CD109 [29-31]. 
TGF-β receptors and Smads are subject of post-translational modifications, including 
phosphorylation, sumoylation and ubiquitylation, which are enzymatically reversible and 
7 
 
regulate these proteins stability and availability, resulting as key determinants to the TGF-β 
cellular responses [19]. Another point of modulation is the regulation of the internalization and 
recycling of the ligand/receptor complexes via lipid rafts/caveolae, which can lead to protein 
degradation in the proteasome [32,33]. On the other hand, a negative feedback loop has been 
well documented, where TGF-βs signaling induces the expression of inhibitory proteins, 
including I-Smads or Smurf ubiquitinases  (E3-ubiquitin ligases that selectively target the 
receptors and Smad proteins for degradation). Thus, BMP signaling induces Smad6 and Smurf1, 
whereas TGF-β1 induces Smad7 and either Smurf1 or Smurf2. In turn, Smad7 inhibits both 
BMP and TGF-β pathways, whereas Smad6 is more selective for BMP signaling showing high 
preference for BMP type I receptors ALK1, ALK3, ALK3 and ALK6  [11].  
In addition to the canonical Smad pathway, the TGF-β signal is determined by a crosstalk with 
non-Smad pathways such as MAP kinase (MAPK), NF-kB, Rho-like GTPase,  
phosphatidylinositol-3-kinase (PI3K)/AKT or hypoxia/HIF-1 [11,34,35].  
2. TGF-β system in health and disease. The TGF-β system regulates a plethora of biological 
processes, including morphogenesis, embryonic development, wound healing or inflammation. 
Alterations of specific component of the TGF-β signaling pathway may contribute to a broad 
range of inherited and non-inherited pathologies such as cardiovascular pathology, fibrosis, 
cancer or congenital diseases. A summary of diseases affecting components of the TGF-β system 
is listed in Table 2. 
2.1. Cardiovascular System. In the cardiovascular system (CV), components of the TGF-β 
pathway  have been implicated in several processes influencing vascular cell proliferation and 
migration, arteriogenesis, angiogenesis, cardiac development and a variety of cardiovascular 
pathologies [36,37]. Genetic studies in mouse have provided much evidence for the TGF-β 
involvement in vascular morphogenesis and dysfunction [36]. Studies in humans have shown the 
TGF-β involvement in hereditary and non hereditary CV diseases: 
Hereditary Hemorrhagic Telangiectasia (HHT), or Rendu-Osler-Weber syndrome, is 
inherited as an autosomal dominant trait involving mainly mutations in ENDOGLIN (ENG) or 
ALK1 genes, whose protein products influence TGF-β family signalling in vascular endothelial 
cells. More than 90% of HHT patients carry a pathogenic mutation in ENG (HHT1) or ALK1 
(HHT2), whilst 1-2% carries a mutation in SMAD4. Interestingly, the same SMAD4 mutations 
also lead to Juvenile Polyposis (JP) resulting in a combined syndrome of JP and HHT (JP-HT) 
[38]. Additional HHT loci have been mapped to chromosome 5q (HHT3) and to chromosome 7p 
(HHT4) [39], whose genes are predicted to encode new components of the TGF-β/BMP 
signalling pathways. HHT is associated with frequent epistaxis, telangiectases in skin and 
mucosa, and arteriovenous malformations (AVMs) in lung, liver, or brain. The pathogenic 
mechanism underlying the generation of telangiectasia and AVMs appears to be 
haploinsufficiency of the HHT genes in endothelia and recent data of transgenic animal models 
of HHT support the existence of a second hit that triggers the generation of these vascular lesions 
[40-42]. 
Loeys-Dietz syndrome (LSD) is an autosomal dominant genetic syndrome caused by mutations 
in the genes encoding ALK5 (LSD type I) or TGFBR2 (LSD type II) [43]. LDS is characterized 
by vascular findings (cerebral, thoracic, and abdominal arterial aneurysms and/or dissections) 
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and skeletal manifestations (pectus excavatum, pectus carinatum, scoliosis, arachnodactyly, joint 
laxity, talipes equinovarus). Approximately 75% of affected individuals have LDS type I with 
craniofacial manifestations (ocular hypertelorism, craniosynostosis, bifid uvula/cleft palate). 
LDS type II patients (25%) show cutaneous manifestations (velvety and translucent skin; easy 
bruising; widened, atrophic scars). The majority of identified mutations are either adjacent to or 
within the serine/threonine kinase domains of ALK5 and TGFΒRII. In three quarters of LSD 
cases, the disorder is the result of a de novo gene mutation. 
Familial thoracic aortic aneurysm syndrome (TADD) is an autosomal dominant disorder of 
large arteries. CV manifestations include dilatation of the aorta at the level of either the 
ascending aorta or the sinuses of Valsalva and aneurysms and dissections of the thoracic aorta 
involving either the ascending or descending aorta. Familial TAAD demonstrates genetic 
heterogeneity and the majority of individuals diagnosed have an affected parent. Two recurrent 
missense mutations affecting the kinase domain of TBRII that lead to familial TAAD have been 
described. TGFBR2 mutations leading to aneurysms and dissections occur predominantly in the 
functionally important kinase domain and are predicted to cause loss of function [44]. 
Pulmonary Arterial Hypertension (PHA) is a disease characterized by elevated pulmonary 
artery pressure leading to right heart failure. PHA demonstrates abnormal remodeling of small 
peripheral resistance vessels in the lung, involving proliferation and migration of vascular 
smooth muscle cells, endothelial cells and fibroblasts. Two types of PHA have been described, 
sporadic or idiopathic PAH (IPAH) and hereditary or familial PAH (FPAH). Both IPAH and 
FPAH are genetically related with a heterozygous germ-line mutation in BMPR2. Mutations in 
the BMPR2 have been associated with 80% of familial PAH and 15-40% of idiopathic PAH. 
Some specific mutations have been identified that affect the ligand binding, transmembrane or 
cytoplasmic domains of BMPR2. Genetic heterogeneity may occur in some cases of severe 
unexplained PAH. In this regard, mutations in ALK1 have also been reported in a few HHT 
families with clinical and histological features of severe PAH, suggesting that mutations in ALK1 
may contribute to PHA [45,46]. 
Atherosclerosis is the primary cause of cardiovascular disease and stroke. Atherosclerosis 
development and progression is a complex process involving endothelial dysfunction, vascular 
inflammation, and accumulation of lipids and cellular debris within the intima of medium and 
large sized arteries, resulting in plaque formation and acute and chronic luminal obstruction. 
Several lines of research support a protective role of TGF-β in atherosclerosis. In animal models, 
deletion of a single Tgfb1 allele gene or reduced availability of TGF-β1 leads to pro-atherogenic 
changes in the blood vessel wall. Conversely, viral delivery of TGF-β1 in an atherosclerotic 
mouse model (Ldlr-/-) suppressed formation of atherosclerotic lesions. In humans, common 
genetic variants in the TGFB1 promoter (such as A-800G and T-509C) have been associated 
with altered plasma levels of TGF-β1, which may contribute to atherosclerosis disease status). 
Activin, similarly to TGF-β1, appears to have a protective role in atherosclerosis development. 
By contrast, BMP2, BMP4 and BMP6 levels are increased in advanced atherosclerotic lesions 
and these elevations are associated with increased levels of calcification, suggesting a role for 
BMPs in promoting advanced atherosclerotic lesions [47,48]. Indeed, MGP (matrix GLA 
protein; inhibitor of BMP) transgenic or MGP-deficient mice have shown that inhibition of BMP 
protects animals from developing atherosclerosis and vascular calcifications [49]. 
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Arterial occlusive diseases are treated by various open and endovascular approaches including 
endarterectomy, atherectomy, bypass graft, balloon angioplasty or stent angioplasty. Upon 
intervention, in a significant number of patients, restenosis displays an exuberant fibrotic 
reaction, intimal proliferation, and vascular remodeling often leading to limb loss or death [50]. 
A critical role for TGF-β in restenosis has been supported by several experimental approaches. 
Thus, overexpression of TGF-β1 in arteries induces neo-intimal hyperplasia and fibrosis [51] and 
animal models with targeted disruption of TGF-β prevent neointima formation and the 
constrictive remodeling associated with angioplasty [52]. Also, Smad7 overexpression attenuates 
collagen deposition, remodeling and contribution of adventitial fibroblasts to neointima 
formation after balloon angioplasty [53]. On the contrary, BMP4 may contribute to graft 
neointimal atrophy by inhibiting smooth muscle cells (SMC) proliferation and increasing SMC 
death in restenosis [54].  
Hypertension is a predominant risk factor for stroke, coronary heart disease, arterial aneurysm 
and chronic kidney disease. In humans, polymorphisms in TGFB1, resulting in increased TGF-
β1 expression, correlate with an elevation in arterial pressure Moreover, TGF-β neutralizing 
antibodies are sufficient to decrease blood pressure and subsequent renal failure in a rat 
hypertension model [37,55]. Activation of the renin-angiotensin-aldosterone system (RAAS) 
contributes to arterial hypertension. Interestingly, TGF-β signaling is upregulated by the RAAS 
axis and angiotensin converting enzyme (ACE) inhibitors and angiotensin I receptor antagonists 
reduce renal TGF-β1 production. Administration of TGF-β neutralizing antibodies and an ACE 
inhibitor, showed a synergistic effect inhibiting renal injury and proteinuria in rats [37,56]. 
BMP6 can enhance angiotensin II-induced aldosterone in human adrenocortical cells, suggesting 
that BMP6 may be involved in aldosterone breakdown induced by chronic treatment with 
angiotensin II receptors antagonists [57]. 
Preeclampsia is a systemic syndrome of pregnancy, clinically characterized by new onset of 
hypertension and proteinuria associated with significant morbidity and mortality to both mothers 
and fetuses. In these patients, plasma levels of soluble endoglin are upregulated and play a major 
pathogenic role, through an anti-angiogenic effect [41]. 
Heart disease involves cardiac remodeling, associated with cardiac hypertrophy and interstitial 
fibrosis, which alters the structural characteristics of the myocardium, leading to the loss of 
normal cardiac function. TGF-β1 is a pivotal modulator of cardiac remodeling by mediating 
cardiomyocyte growth, myofibroblast activation and ECM production, which underlie the 
development of myocardial fibrosis [37,58]. Multiple cardiac disorders have been linked to 
alterations in TGF-β/BMP signaling pathways. In humans, heterozygous loss-of-function 
mutations in the GDF1 contribute to cardiac defects in tetralogy of Fallot (TOF) [59], while 
mutations in TGFB3 have been related with the arrhythmogenic right ventricular dysplasia-1 
(ARVD) [60]. Moreover, TGF-β1 may act as a downstream target of angiotensin signaling, 
mediating Angiotensin II-induced hypertrophy Angiotensin II promotes cardiomyocyte and 
fibroblast proliferation concomitant with an increased expression of ECM proteins [37, 58] and 
clinical trials have documented the beneficial effects of angiotensin II inhibition in patients with 
myocardial infarction and heart failure. Of note, increased circulating levels of TGF-β1 are found 
in patients with dilated, hypertrophic and restrictive cardiomyopathy. Compatible with this 
finding, polymorphisms in TGFB1 that result in increased TGF-β1 expression have been linked 
to dilated cardiomyopathy [61]. Similarly, a polymorphism in BMP10, which leads to increased 
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BMP10 levels, was identified in patients with dilated cardiomyopathy [62]. GDF15 has been 
involved in heart diseases and in vitro experiments suggest that GDF15 is a cardioprotective 
cytokine [63]. Patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) have 
significantly elevated circulating levels of GDF15. In addition, patients who had died from a 
myocardial infarction show markedly enhanced GDF15 levels in the ischemic myocardium, 
suggesting that GFD15 may be a biomarker for heart diseases [64].  
2.2. Fibrotic and inflammatory diseases. Abnormal TGF-β regulation and function are 
implicated in a growing number of fibrotic and inflammatory pathologies, including pulmonary 
fibrosis, liver cirrhosis, glomerulonephritis and diabetic nephropathy, congestive heart failure, 
rheumatoid arthritis, Marfan syndrome, hypertrophic scars, systemic sclerosis (SSc), myocarditis 
and Crohn's disease [37,65,66]. Multiple lines of evidence involve TGF-β as a critical regulator 
of both physiologic fibrogenesis and pathological fibrosis. The fibrotic reaction is characterized 
by an increased production of ECM components, such as fibronectin, collagen, laminin and 
vitronectin, as well as proliferation, migration and accumulation of mesenchymal cells. These 
processes result in the activation of local fibroblasts to differentiate into myofibroblasts, which 
are a specialized type of ECM producing cells [65]. An important effector of TGF-β-induced 
fibrosis is connective tissue growth factor (CTGF). TGF-β induces CTGF expression in 
fibroblasts, which promotes collagen synthesis and myofibroblast differentiation [65]. Moreover, 
CTGF binds directly to TGF-β, and enhances its activity resulting in increased binding to TBRI 
and TBRII [67]. Smad3 has been identified as an intracellular mediator of TGF-β-induced 
fibrosis. Indeed, TGF-β signaling through Smad3 directly promotes expression of type I 
collagen, a major component of the ECM, during fibrosis [68]; Smad3 is required for angiotensin 
II-induced vascular fibrosis; and Smad3-/- knockout mice are resistant to bleomycin- and TGF-β-
mediated pulmonary fibrosis and to skin injury from ionizing radiation [69].  
TGF-β plays a key role in pulmonary and hepatic fibrosis, not only through its ability to attract 
fibroblasts and stimulate their proliferation, but also through induction of EMT in alveolar 
epithelial cells and transdifferentiation of quiescent hepatic stellate cells into myofibroblasts, 
respectively [70]. In addition, the endothelial to mesenchymal transition may contribute to TGF-
β-induced cardiac fibrosis [71,72]. Progression of diabetic nephropathy (DN) to end-stage 
kidney disease is manifested by the scarring of the renal glomerulus, followed by a fibrotic 
process in the tubulointerstitial region [73]. Elevated levels of the three isoforms of TGF-β are 
observed in glomerular and tubulointerstitial compartments of patients with established DN, 
suggesting that increased renal TGF-β levels closely correlate with the degree of mesangial 
matrix expansion, interstitial fibrosis, and renal insufficiency. Moreover, TGF-β1 was increased 
four-fold in the urine of diabetic versus non-diabetic patients, suggesting that overproduction of 
TGF-β1 in the kidneys, may contribute to DN [65,74].  
2.3. Pulmonary diseases. The lung is the main organ of respiration in air-breathing animals. In 
mammals, the exchange of gases with the blood takes place in alveoli, which are hollow 
spherical outcroppings of the respiratory bronchioles.  Disturbances to the alveolar architecture 
have serious consequences, as exemplified by human diseases such as bronchopulmonary 
dysplasia (BPD), emphysema, chronic obstructive pulmonary disease (COPD) and asthma 
[75,76]. 
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BPD is a chronic lung disease in prematurely born infants, which is an important cause of 
morbidity and mortality. Patients who survive with BPD often show obstructive airway disease, 
pulmonary hypertension, and delay of growth and development [77]. Although TGF-β is an 
important mediator during development of the normal early lung patterning, excessive TGF-β 
signaling may negatively affect alveologenesis during pulmonary development. Thus, in 
premature babies with lung injury, the level of TGF-β in the bronchoalveolar lavage is increased 
and correlates with the severity of BPD. Furthermore, increased TGF-β levels have been 
observed in the peripheral areas of lungs from babies with BPD [76]. Also, overexpression of 
TGF-β1 in animal models induces a pathology that closely resembles BPD in human neonates 
[78]. These results suggest that TGF-β is a therapeutic target for the treatment of BPD.  
COPD is the fourth leading cause of death in the developed world; it is characterized by 
irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways 
disease [76]. Genetic studies have identified TGF-β as a promising candidate gene related to 
COPD based on association analyses between SNPs in the TGFB1 gene and COPD phenotypes 
and a case-control study In addition, increased expression of TGF-β1 and decreased expression 
of the inhibitory Smad6 and Smad7 in the airway epithelium of patients with chronic bronchitis 
or COPD has been reported. Interestingly, increased TGF-β1 expression in airway epithelial cells 
from patients with COPD and smokers correlated with the burden of cigarette smoking, 
suggesting that TGF-β effects in airway remodeling and fibrosis may be provoked by cigarette 
smoke [75]. 
Asthma is a chronic inflammatory disorder of the airways characterized by structural changes 
(remodeling) of the airway wall. Airway remodelling is characterized by subepithelial fibrosis 
with thickening of basement membrane in areas of proximal airways. TGF-β1 signaling is 
increased in the lungs of asthmatics, which is in agreement with the increased activity of this 
cytokine in asthma pathogenesis. Conversely, experiments with animal models suggest that 
airway remodelling in asthma may be prevented or reversed using agents which block TGF-β 
signaling [75]. 
Idiopathic pulmonary fibrosis (IPF) is one form of diffuse parenchymal lung diseases 
(DPLD) characterized by progressive dyspnea and whose pathogenesis and mortality correlate 
with TGF-β1 levels. Although TGF‑β1 polymorphism does not predispose to the development of 
IPF, increased TGF-β1 levels play an important role in the progression of fibrosis and might 
cause shorter survival [79]. 
2.4. Bone and muscle diseases. Bones constitute a mineralized organ that plays key roles in 
human physiology providing mechanical support to the movement, regulating blood calcium 
levels, protecting various organ systems and sheltering hematopoiesis. Bone tissue is 
continuously remodeled by the mineralization activity of osteoblasts and the bone resorbing 
activity of osteoclasts [80]. TGF-β superfamily members are abundantly expressed in the bone 
environment where they regulate important processes. TGF-β1 has been implicated in the 
regulation of osteoblast proliferation, differentiation and apoptosis. Survivors of TGF-β1 knock-
out mice have reduced bone growth and mineralization, as well as decreased serum levels of 
bone alkaline phosphatase, a bone turnover marker [37]. Severe anomalies in bone development 
were observed in BMP2 and BMP4 knockout mice [81] and mice lacking Acvr2 or Acvr2b gene 
show multiple bone defects. Some Acvr2-null mice exhibit hypoplasia of the mandible and other 
12 
 
skeletal abnormalities [8]. Bmpr1b-deficient Gdf5-null mice are viable, but exhibit short limbs 
and abnormal digit cartilage [82]. In humans, genetic studies have shown the involvement of 
TGF-β superfamily signaling in several hereditary diseases affecting bone and muscle [37]. 
Camurati-Engelmann disease (CED) is an autosomal dominant disorder characterized by 
hyperostosis of the long bones and the skull, proximal muscle weakness, severe limb pain, a 
wide-based waddling gait, and joint contractures. More than 90% of CED patients have 
mutations in TGFB1. The majority of these mutations lead to single amino-acid substitutions in 
the carboxy terminus of TGF-β1 LAP, which may disrupt LAP dimerization and binding to 
active TGF-β1, leading to increased active TGF-β1 release from the cell and TGF-β-mediated 
transcription [78,83]. 
Osteoporosis is the most common age-related skeletal chronic disorder, characterized by 
reduced bone mass and increased risk of low-trauma fractures. Fragility fractures in osteoporosis 
represent a major cause of morbidity and mortality. TGFB1 is a candidate target gene in 
osteoporosis with relevant polymorphisms located in the promoter region (-1348C/T and -
509C/T) and in exon 1 (29T/C, L10P and 74G/C, R25P). Additional single-nucleotide 
polymorphisms associated with osteoporosis have been identified in TGFBR1, TGFBR2, 
SMAD2, SMAD3, SMAD4 and SMAD7 [84,85]. 
Brachydactyly type A2 (BDA) is an autosomal dominant malformation characterized by 
shortening and deviation of the index fingers and the first and second toes. Mutations in the GS 
or kinase domains of the BMPR1B gene, acting in dominant-negative manner, are responsible for 
the bone malformation in BDA [86]. Mutations in GDF5 cause Brachydactyly type C (BDC), 
an autosomal dominant disorder characterized by an abnormal shortness of the fingers and toes 
defects [87] as well as acromesomelic chondrodysplasia Hunter-Thompson type (AMDH), an 
autosomal recessive form of dwarfism, characterized by normal axial skeletons and missing or 
fused skeletal elements within the hands and feet. Also, a mutation in GDF5 (R438L) is 
responsible for proximal symphalangism, showing fusion of carpal and tarsal bones and 
ankylosis of the proximal interphalangeal joints. Du Pan Syndrome is originated by defects in 
GDF5. This syndrome, also known as fibular hypoplasia and complex brachydactyly is a rare 
autosomal recessive condition characterized by absence of the fibulae and severe acromesomelic 
limb shortening with small, non-functional toes [88].  
Mutations in ALK2 cause fibrodysplasia ossificans progressiva (FOP), an autosomal dominant 
disorder with skeletal malformations and progressive ossification in muscular tissues [89]. A 
heterozygous mutation in ALK2 (R206H) is frequently found in individuals with FOP and 
results in hyperactivation of the ALK2 kinase. Interestingly, a transgenic mouse model, 
expressing constitutively active (ca) ALK2 in muscle, mimics the phenotype of human FOP and 
intramuscular expression of caALK2 results in ectopic bone formation, joint fusion and 
functional impairment [90]. 
A heterozygous mutation in GDF6 is responsible for the autosomal dominant Klippel-Feil 
syndrome [91], characterized by fusion of vertebral bodies C2 and C3. Spondylocostal 
dystostosis 4 (SCDO4) presents hemivertebrae and rib malformations, as well as heterozygosity 
for a mutant GDF6 allele, predicted to result in K424R substitution at a highly conserved residue 
in the propeptide domain [92]. 
13 
 
Skeletal muscle is a form of striated muscle tissue existing under control of the somatic nervous 
system. GDF8/Myostatin is highly expressed in skeletal muscle and has been implicated in 
human muscle diseases characterized by fibrosis such as muscular dystrophy [93]. Duchenne 
muscular dystrophy (DMD) is the most common inherited lethal myopathy. DMD patients lose 
their ability to walk by the age of 12 years and die during their twenties due to either cardiac or 
respiratory failure. The disorder is caused by pathogenic mutations in the dystrophin gene, but 
additional polymorphisms in GDF8/Myostatin were identified in DMD patients [94]. 
GDF8/Myostatin is a muscle-specific ligand that negatively regulates muscle growth. 
Accordingly, GDF8/Myostatin mutations are associated with gross muscle hypertrophy [95] and 
disruption of endogenous GDF8/Myostatin by gene targeting in mice results in increased muscle 
mass and stronger muscle [96]. These observations suggest that myostatin is a potential 
therapeutic target for treating the symptoms in muscular dystrophy patients. 
2.5. Reproductive disorders. TGF-β superfamily members play critical roles in the female 
reproductive system, regulating ovarian follicle development, primordial follicle recruitment, 
gonadotropin receptor expression, granulose and theca cell proliferation, oocyte maturation, 
ovulation, luteinization, and corpus luteum formation [97]. Not surprisingly, deregulation of 
TGF-β superfamily signaling results in several reproductive disorders.  
Premature ovarian failure (POF) is characterized by cessation of menstruation for at least 4 
months and symptoms of hypoestrogenism and elevated gonadotropins before the age of 40 
years. POF occurs in up to 1% of women and is a common cause of infertility [98]. BMP15 is 
crucial in folliculogenesis and follicle differentiation in mammals [99]. A heterozygous mutation 
in BMP15 has been identified in two sisters with primary amenorrhoea and the mutant BMP15 
protein (Y235C) antagonizes the activity of normal BMP15 leading to a decreased proliferation 
of granulosa cells [100]. Additional BMP15 variants have been identified in POF patients [101]. 
Most of these mutations involve the propeptide region and lead to a defective production of 
bioactive BMP15, providing further support for their implication in the development of POF. 
Moreover, inhibin-A is one of the most important regulators of the female reproductive cycle 
[102] and one mutation in the inhibin alpha gene (INHA) has been identified in patients with 
FOP, resulting in an inactive mutant protein (A257T).  
The persistent Mullerian duct syndrome (PMDS) is a rare form of inherited male 
pseudohermaphroditism characterized by the presence a uterus and sometimes other Müllerian 
duct derivatives in otherwise normally masculinized XY males [12]. The phenotype can be 
produced by a mutation in the gene encoding anti-mullerian hormone (AMH, PMDS-I) or by a 
mutation in the AMH receptor (PMDS-II). Mutations in either AMH or AMHR2 produce 
indistinguishable clinical symptoms. AMH is expressed almost exclusively by the somatic cells 
of the gonads from both sexes. In males, AMH is highly expressed by Sertoli cells from their 
differentiation to the onset of puberty, whereas in females, AMH is synthesized by granulose 
cells of growing follicles from birth to menopause [13]. In PMDS-I, markedly low levels of 
circulating AMH are observed, due to homozygous or heterozygous mutations. In PMDS-II, 
mutations in AMHR2 may lead to a soluble unstable receptor or to the disruption of the substrate-
binding site in the kinase domain [13]. 
2.6. TGF-β in Cancer. TGF-β has a tumor suppressive role at early stages of tumor 
development by virtue of its potent growth inhibitory effect on epithelial and lymphoid tissues, 
from which most human cancers arise. In addition to the control of cell cycle, TGF-β exerts other 
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type of effects in individual cells and tissues in order to protect them from tumorigenesis. For 
example, TGF-β induces either apoptosis or replicative senescence depending on the cell type, 
and inhibits the production of paracrine mitogenic factors by stromal cells. It is also involved in 
the maintenance of genomic stability and, even, in the preservation of the normal tissue 
architecture; i.e., in the colon [103]. However, tumor cells evade the TGF-β suppressive action 
by different mechanisms and, paradoxically, TGF-β becomes a pro-oncogenic factor that 
stimulates tumor cell growth and invasiveness at later stages of tumorigenesis. The pro-
oncogenic activities of TGF-β are exerted at both compartments, the tumor and the stroma. Thus, 
TGF-β stimulates tumor cell proliferation by inducing the production of autocrine mitogenic 
growth factors, such as platelet-derived growth factor B (PDGF-B). It also induces epithelial-
mesenchymal transitions associated with the acquisition of motility and invasive properties, and 
promotes the formation of distal metastasis by a variety of mechanisms [104]. In addition, in the 
tumor stroma, TGF-β stimulates the generation of myofibroblasts from mesenchymal precursors, 
the so called cancer-associated fibroblasts that facilitate tumor cell proliferation, invasion and 
promote neoangiogenesis. Also, by its immunosuppressive actions TGF-β helps cancer cells to 
evade the immune surveillance. There are recent and excellent reviews addressing the wide range 
of TGF-β roles in cancer as well as the molecular basis involved [105-107], and, therefore, these 
topics will not be discussed herein. 
Several components of the TGF-β signalling pathway are inactivated in subsets of pancreatic, 
colorectal, gastric, ovarian, and head and neck tumors, which disable the tumor suppressive 
action of TGF-β [108]. In individuals with familial syndromes, germline mutations in some of 
these tumor suppressor genes have also been found. In this article, we only will review germline 
inactivation of components of the TGF-β pathway that predispose to cancer. Interestingly, all the 
familial syndromes bearing mutations in genes of the TGF-β/BMP system predispose to 
colorectal or gastric cancer.  
Hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome is an autosomal 
dominant disorder caused by mutations in the DNA mismatch repair system, mainly the MLH1 
and MSH2 genes, that leads to replication errors and hence microsatellite instability (MSI). 
HNPCC accounts for 1-6% of the total colorectal cancer incidence worldwide [109]. MSI 
predominantly affects mono, di- and tri-nucleotide tracts and short sequence repeats by 
accumulating mutations at these repeats. The TGFBR2 gene contains such “microsatellite-like” 
sequences in exon 3 that encodes a 10-base pair polyadenine repeat in TBRII (BAT-RII). BAT-
RII mutations that lead to a truncated receptor lacking the transmembrane and the intracellular 
kinase domains have been identified at a high frequency in HNPCC [110] and other MSI-
associated cancers [108]. 
Juvenile polyposis syndrome (JPS) is also an autosomal dominant syndrome characterized by 
multiple hamartomatous polyps occurring throughout the gastrointestinal tract. Unlike 
adenomatous polyps, hamartomatous polyps (dilated cystic glands with retention of mucus) are 
considered to be non-neoplastic. However, JPS is associated with increased risk of developing 
gastric, colorectal and pancreatic malignancies [111]. Two genes of the TGF-β/BMP signalling 
system, MADH4 and BMPRIA, encoding Smad4 and a transmembrane type I receptor for BMPs 
(ALK3), respectively, are responsible for JPS. Germline BMPRIA and MADH4 mutations 
account each for about 20% of JPS cases. MADH4 mutations are clustered in the region 
encoding the protein MH2 domain involved in Smad oligomerization. In BMPRIA, most 
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alterations are microdeletions or non-sense mutations that lead to the synthesis of a truncated 
protein [108]. Germline mutations in the ENG gene encoding the TGF-β co-receptor endoglin 
have also been found at low frequency in JPS patients who do not have BMPRIA and MADH4 
mutations. Nevertheless, there is no consensus to consider ENG as a JPS susceptibility gene 
[112, 113]. 
Hereditary mixed polyposis syndrome (HMPS) is another autosomal dominantly inherited 
syndrome characterized by mixed “adenomatous/hyperplastic/atypical juvenile” polyps. 
Germline BMPRIA mutations have also been found in some HMPS families. The fact that 
BMPRIA mutations are also involved in JPS, and that JPS and HMPS are two well defined 
clinical entities, suggests that inactivation of the type I BMP receptor is the initiating event for 
both disorders that predispose to colorectal tumorigenesis [109].  
3. Therapeutic interventions targeting the TGF-β signaling pathway. As explained above, 
the TGF-β signaling pathway is an attractive target for therapy in a number of diseases, including 
fibrotic and cardiovascular diseases or cancer. Depending on the specific disease, the therapeutic 
approach may involve the inhibition of the pathway or its enhancement. Inhibition treatments 
include ligand traps, such as ligand specific neutralizing antibodies, soluble ligand receptors, 
antisense-dependent silencing of ligands and chemical inhibitors that block kinase activity of 
TGF-β family members receptors. Conversely, increased ligand-dependent signaling may be 
beneficial for therapeutic purposes as it is the case of recombinant human BMPs that activate the 
bone regenerative properties of the BMP pathway [114]. A summary of the current clinical trials 
is shown in Table 3 and Figure 3. Further information can be obtained from the NIH webpage 
(http://clinicaltrials.gov). 
3.1. Ligands traps. 
3.1.1. Neutralizing antibodies. The pan-TGF-β antibody GC-1008 (Genzyme Inc.) was tested in 
a phase I clinical study of patients with renal cell carcinoma or malignant melanoma 
(NCT00356460). Treatment was well tolerated with mainly grade 1-2 toxicity including skin 
rash, fatigue, headache and gastrointestinal symptoms. Some patients achieved stable disease or 
improved [115]. A phase II trial is ongoing for the treatment with GC-1008 of Pleural Malignant 
Mesothelioma (NCT01112293) and a phase I clinical study has been completed for the treatment 
of Focal Segmental Glomerulosclerosis (NCT00464321), which is associated with nephrotic 
syndrome in children and adolescents and it is an important cause of kidney failure in adults. 
Moreover, GC-1008 is ready to enter in phase I trials for idiopathic pulmonary fibrosis. 
3.1.2. Antisense. Another approach which has entered clinical trials inhibits TGF-β function by 
means of antisense oligonucleotides (AS-ODNs). The anti-tumorigenic effect of AS-ODNs was 
supported by phase I/II trials with the TGFB2 antisense compound AP12009 (Trabedersen; 
Antisense Pharma). In comparison to standard chemotherapy, treatment with AP12009 resulted 
in prolonged survival of patients with anaplastic astrocytoma, and a phase III is ongoing 
(NCT00761280) [116]. Accordingly, patients with high-grade glioma showed a higher survival 
rate at 24 months and showed significantly more responders after 14 months when treated with 
AP12009 as compared to standard chemotherapy protocols; a phase II trial is completed 
(NCT00431561). Another phase I study (NCT00844064) to evaluate the treatment with 
AP12009 of pancreatic neoplasms, melanoma and colorectal neoplasms is ongoing. 
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A phase II trial with Lucanix (NovaRx Corporation), a TGF-β2 antisense gene-modified 
allogeneic tumor vaccine, is completed in patients with advanced non-small cell lung cancer 
(NCT01058785) and a phase III is ongoing (NCT00676507). Interestingly, a novel approach is 
being tested in a phase I trial (NCT00684294), using a combination of GMCSF and antisense 
TGFB2 autologous tumor cell vaccine for the treatment of Advanced Metastatic Carcinoma. Is it 
expected that GMCSF overexpression stimulates expression of tumor antigens in tumor cells and 
dendritic cell migration, whereas TGF-β2 blockade by TGFB2 antisense may allow for a better 
immune response at the vaccine site. 
3.1.3. Soluble receptors. TGF-β1 is one of the main mediators in the fibrotic process, associated 
to both scarring and a long list of pathologies related to chronic inflammation affecting several 
organs and tissues. ISDIN has developed a 14mer peptide (P144) from human betaglycan 
designed to block the interaction between TGF-β1 and the signaling receptors, thus modulating 
TGF-β1 biological effects. Two phase II clinical studies are ongoing for the treatment of skin 
fibrosis in Systemic Sclerosis (NCT00574613 and NCT00781053). 
Aceleron-Pharma has generated a recombinant fusion protein by joining a portion of the human 
ActRIIB receptor to a portion of the human immunoglobulin (ACE-031). This creates a decoy 
version of ActRIIB which interferes with ligands, such as GDF8/Myostatin, thus allowing the 
muscle growth [117]. A phase II trial is ongoing in patients with Duchenne Muscular Dystrophy 
(NCT01099761), and a phase I trial is ongoing in healthy postmenopausal women with 
unexplained weight loss (NCT00952887).  
3.1.4. Receptors inhibitors. Most of the current strategies to inhibit TGF-β signaling at the 
receptor kinase level include the use of small molecule inhibitors, which bind to the ATP binding 
domain of the receptors [118]. A number of companies have developed ATP-mimetic drugs that 
target the kinase catalytic site of TBRI/ALK5. Although these small inhibitors are not 
completely specific, they are very effective at inhibiting Smad2/3 phosphorylation. Preclinical 
studies in vitro and in vivo have shown the efficacy of these compounds in prevention and cure 
of several experimental diseases. The TBRI/ALK5 and TBRII dual inhibitor LY2157299 is now 
in phase I trial in patients with metastatic malignancies to determine the safety and 
pharmacokinetics of the compound. 
An interesting approach is ongoing in a phase I trial to relapse Epstein-Barr virus (EBV)-positive 
lymphoma (NCT00368082). Autologous or allogeneic latent membrane protein (LMP)-specific 
cytotoxic T-cells have been retroviral genetic modified to express a dominant negative TBRII 
(DNRII) to render them resistant to the immunosuppressive effects of TGF-β. 
Tumors require new blood vessels to support their ability to grow and metastasize. New 
treatments aimed at preventing these blood vessels have the ability to improve the clinical 
management of cancer. Since its expression is mostly restricted to endothelial cells, ALK1 and 
endoglin represent promising targets for anti-angiogenic therapies in cancer [18,36]. Although no 
in vitro data about specific ALK1 inhibitors have been published so far, a clinical phase I study 
testing a human anti-ALK1 antibody PF-03446962 (Pfizer) in patients with advanced solid 
tumors is ongoing (NCT00557856). A phase I trial using a human/murine chimeric anti-endoglin 
monoclonal antibody TRC105 (Tracon Pharmaceuticals Inc.) in patients with solid cancer is 
ongoing (NCT00582985). Treatment was well tolerated with mainly grade 1-2 toxicity including 
fatigue, anemia, proteinuria and diarrhea. One patient with hormone refractory prostate cancer 
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obtained a complete prostate-specific antigen (PSA) response and 3 patients had prolonged stable 
disease [119]. 
When increased BMP signaling contributes to disease pathogenesis, inhibitors may offer 
therapeutic benefit, as it is the case of fibrodysplasia ossificans progressiva (FOP). Inhibition of 
Smad phosphorylation by BMPR-I intracellular kinase domains with small molecules may 
provide more efficient signal transduction pathway inhibition. Preclinical studies have shown the 
efficacy of Dorsomorphin, which selectively inhibits BMP signaling from ALK1, ALK2, 
BMPR-IA/ALK3 and BMPR-IB/ALK6, and blocks BMP-induced Smad1/5/8 phosphorylation 
Also, Dorsomorphin optimized derivatives LDN-193189 or DM-3189 with higher activity and 
specificity for BMP type I receptors have been developed LDN-193189 has shown promising 
results in a mouse model of FOP; it inhibits activation of Smad1/5/8 induced by the caALK2, 
leading to a reduction in ectopic ossification and functional impairment in mice [8]. 
3.2. Recombinant ligands. Based on animal studies demonstrating dramatic increases in fusion 
mass and quality of bone regeneration using BMPs [8], clinical trials in humans have been 
initiated. Although animal models have shown osteo-induction with various BMPs, including 
recombinant human BMP2, BMP7 and BMP9, as well as whole BMP extract from human bone, 
clinical trials have primarily been limited to BMP2 and BMP7 (rhOP-1). BMP2 is being used in 
the treatment phase I of degenerative Lumbar Disc Disease, Spondylolisthesis and Spinal 
Stenosis (NCT00405600); in phase II of Degenerative Disc Disease (NCT00707265); in phase I 
Osteoarthritis (NCT00243295); and in Osteoporosis (NCT00752557). A phase II trial is ongoing 
for the treatment of Osteoarthritis of the Knee with BMP7 (NCT0111104). In addition, two 
clinical studies in phase II are in progress by using GDF5/BMP14 for the treatment of 
Degenerative Disc Disease (NCT00813813; NCT01124006), and one in phase I/II for the 
treatment of early Lumbar Disc Degeneration (NCT01158924). 
3.3. Other preclinical approaches to regulate TGF-β signaling. Disruption of the intracellular 
Smad signaling may become a relevant strategy to control TGF-β superfamily signaling. Several 
preclinical studies have assessed the efficacy of endogenous/synthetic Smad inhibitors, Smad 
sequestration or targeting degradation in several diseases in vitro and in vivo [118]. Hepatocyte 
growth factor (HGF) exerts anti-fibrotic effects by opposing TGF-β1/Smad signaling. Induction 
of the inhibitory Smad7 by HGF, treatment with the HGF synthetic analog BB3 (Angion 
Biomedica Corp) and gene transfer of Smad7 showed antifibrotic properties in animal models 
[120,121]. Also, Paclitaxel/Taxol, an anticancer drug that stabilizes the microtubules, attenuated 
hepatic fibrosis by inhibiting TGF-β signaling [122]. 
In addition to Smads, other signalling pathways downstream of TGF-β provide novel 
opportunities for TGF-β-targeting therapies. This is the case of the protein tyrosine kinase c-
Abelson (c-Abl) that is activated by TGF-β in fibroblasts and mediates some of the Smad-
independent profibrotic effects. In Systemic Sclerosis c-Abl was found to be constitutively 
phosphorylated in the skin lesions of patients. Interestingly, Imatinib has been shown to block 
the induction of c-Abl activity and fibrotic gene responses elicited by TGF-β in explanted 
Systemic Sclerosis fibroblasts. Moreover, the anti-TGF-β effects of Imatinib are also associated 
with the inhibition of Smad1 activation [118]. 
A growing interest exists in using commonly used drugs for anti-TGF-β therapy (Table 3). For 
example, the anti-hypertensive drug Losartan, an angiotensin II receptor blocker, has been 
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reported to antagonize TGF-β signaling through inhibition of the renin-angiotensin axis. 
Accordingly, Losartan reduced aortic wall thickness by suppression of local TGF-β signaling in 
a mouse model of Marfan syndrome. A pathogenic role for excess TGF-β1 levels in diabetic 
nephropathy has been postulated. In order to counteract the excess of TGF-β in this disease, a 
clinical study using the ACE inhibitor captopril was carried out. Serum TGF-β1 levels decreased 
significantly in the captopril-treated group. Furthermore, the captopril-treated patients showed a 
better preserved renal function. These results suggest that TGF-β1 plays a pivotal role in the 
progression of diabetic nephropathy and that, by lowering TGF-β1 production, the ACE inhibitor 
therapy may protect the kidney. Morover, Tranilast, which is currently used for the treatment of 
asthma, allergic rhinitis and atopic dermatitis, inhibiting mast cell degranulation, has shown a 
potent anti-fibrotic effect in sclerotic fibroblasts and in animal models of fibrosis. In addition, 
Tranilast showed beneficial effects preventing strictures progression in the treatment of Crohn’s 
disease [66]. These effects are likely mediated by the Tranilast inhibition of TGF-β1 secretion 
and Smad activation. 
Another line of investigation is based on histone deacetylase (HDAC) inhibitors. In cancer, the 
loss of TGF-β signaling occurs early in carcinogenesis and contributes to tumor progression. The 
loss of TGF-β responsiveness frequently involves the TGFBR2, whose expression is silenced 
through epigenetic mechanisms. Thus, re-expression of TGFBR2, by using HDAC inhibitors as 
epigenetic therapies, aims to activate the tumor suppressive role of the TGF-β signal pathway. 
Indeed, the treatment of cancer cell lines resistant to TGF-β-induced growth inhibition, with 
HDAC inhibitors 5 aza-2′ deoxycytidine, MS275, TSA and sodium butyrate successfully restores 
the expression of TGFBR2 [123]. 
 
Conclusions 
The core molecular components of the TGF-β/Receptors/SMAD signaling pathway and the 
phylogenetically conserved mechanisms of intracellular signal transduction have been well 
characterized. Nonetheless, one of the current challenges is to understand the differential 
functional responses of cell context-dependent inputs into the core pathway. A better 
comprehension as to how modulatory stimuli shape a functional cell response will require a 
further detailed analysis of the endogenous signaling in vivo and in vitro, including the ligand 
bioavailability and sensing by receptors as well as the characterization of possible cross-talks 
with other signaling pathways. These studies may provide novel molecular targets for treatment 
of diseases caused by malfunctioning of the TGF-β signaling pathway such as cardiovascular, 
fibrosis, reproductive, cancer or wound-healing disorders. In addition, identification of small 
molecules (inhibitors and potentially activators) of TGF-β signaling using high-content 
screenings raises new hopes for future therapeutic interventions. 
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FIGURE LEGENDS 
 
Figure 1. Schematic representation of the mammalian TGF-β family. The figure represents the 
four major groups of TGF-β family members, including TGF-βs, Activins/Inhibins, BMPs and 
AMH/MIS.  
Figure 2. The TGF-β signaling pathway. The upper panel represents the different ligands, 
signaling receptors (type I and II), auxiliary receptors (type III) and Smad proteins (R-Smad, Co-
Smad and I-Smad). The bioavailability of the ligand and the core signaling receptor formed by 
the heterodimeric association between type I and type II receptors determines the specificity of 
the signaling. The type I receptor acts downstream of the type II by phosphorylating specific R-
Smads. Thus, activation of ALK1, ALK2, ALK3 and ALK6 leads to phosphorylation of Smad1, 
Smad5 and Smad8, while activation of ALK4, ALK5 and ALK7 phosphorylates Smad2 and 
Smad3. Phosphorylated (-P) R-Smads associate with Smad4 in heteromeric complexes that are 
translocated to the nucleus where they regulate specific gene expression responses by binding to 
gene promoters together with other DNA binding transcription factors. The red star indicates the 
Ser/Thr kinase activity in the receptors. GTM, general transcription machinery. 
Figure 3. Therapeutic targets in the TGF-β signaling pathway. The figure represents several 
therapeutic approaches that target different components of the TGF-β signaling pathway, 
including antibodies, antisense oligonucleotides, soluble receptors, recombinant ligands or 
chemical kinase inhibitors. For further details of the specific drugs, see Table 3. 
 Table 1. TGF-β Signaling and Auxiliary Receptors, their Ligands and R-
Smads 
Type I receptors Ligands R-Smads 
ALK1/ ACVRL1 TGF-β, BMP9, BMP10 Smad1,5,8 
ALK2/ ACVR1 BMPs, GDFs Smad1,5,8 
ALK3/ BMPR1A BMPs Smad1,5,8 
ALK4/ ACVR1B Activins, Myostatin/GDF8, 
GDF11 
Smad2,3 
ALK5/ TGFBR1 TGF-βs, Myostatin/GDF8, 
GDF11 
Smad2,3 
ALK6/ BMPR1B BMPs Smad1,5,8 
ALK7/ ACVR1C BMP16/Nodal Smad2,3  
Type II receptors 
TGFBR2/TBRII TGF-βs 
BMPR2/ BMPRII BMPs, GDFs 
ACVR2/ ActRIIA Activins, BMP2, BMP4, 
BMP7, GDFs 
ACVR2B/ ActRIIB Activins, BMP2, BMP4, 
BMP7, GDFs, BMP16/Nodal 
AMHR2/ AMHR II AMH 
Type III receptors 
Betaglycan TGF-β1, TGF-β2, TGF-β3, 
Activin-A, BMP2, BMP4, 
BMP7, GDF5 
Endoglin TGF-β1, TGF-β3, Activin-A, 
BMP2, BMP7, BMP9 
 
 
Table 2. Human disease-causing mutations in TGF-β family ligands, receptors, 
and signaling proteins 
Protein/Gene 
(OMIM ID#) 
Disease (OMIM ID#; Genecard; References) Line of mutation 
Ligands 
TGF-β1 
(#190180) 
Camurati-Engelmann disease (#131300) Germ line 
TGF-β2  
(#190220) 
Peters anomaly (#604229) Chromosomal 
aberration  
TGF-β3 
(#190230) 
Arrhythmogenic right ventricular dysplasia-1  
(#107970) 
Germ line 
BMP4 
(#112262) 
Anophthalmia-microphthalmia and/or retinal dystrophy 
(#607932) 
Cleft lip and cleft palate (#600625) 
Germ line 
BMP7  
(#112267) 
Ocular, brain, ear, palate, and skeletal anomalies (Wyatt et al., 
2010; Hum. Mutat. 31, 781-787) 
Germ line 
BMP13/GDF6 
(#601147) 
Klippel-Feil syndrome (#118100) 
Spondylocostal dysostosis-4 - isolated (#122600) 
Microphthalmia (#613094) 
Germ line 
BMP14/ GDF5  
(#601146) 
Hunter-Thompson type chondrodysplasia (#201250) 
Grebe type chondrodysplasia (#200700) 
Brachydactyly type C (#113100) 
Multiple-synostosis syndrome (#186500) 
Du Pan syndrome (#228900) 
Germline 
BMP15 
 (#300247) 
Ovarian dysgenesis (#300510) 
Premature ovarian failure 4 (#300510) 
Germ line 
GDF1 
(#602880) 
Tetralogy of Fallot (human congenital heart defects) ( #187500) Germ line 
GDF3 
(#606522) 
Microphthalmia, anophthalmia and colobomata (Ye et al., 2010; 
Hum. Mol. Genet. 19, 287-298) 
Germ line 
GDF5  
(#601146) 
Du Pan type chondrodysplasia (#228900) 
Brachydactyly type C (#113100) 
Proximal symphalangism (#185800) 
Germ line 
GDF6  
(#601147) 
Klippel-Feil syndrome (#118100) 
Spondylocostal dystostosis 4 (#122600) 
Germ line 
GDF8/Myostatin 
(#601788) 
Muscle hypertrophy (Schuelke et al., 2004; N. Engl. J. Med. 
350, 2682-2688) 
Duchenne muscular dystrophy (#310200) 
Germ line 
GDF9 
(#601918) 
Premature ovarian failure (#300510) Germ line 
Inhibin alpha 
(#147380) 
Premature ovarian failure (Chand et al., 2010; Hum. Reprod. 
Update. 16, 39-50) 
Somatic 
Anti-Mullerian 
Hormone 
(#600957) 
Persistent mullerian duct syndrome (#261550) Germ line 
Type I receptors 
ALK1/ ACVRL1 
(#601284) 
Hereditary hemorrhagic telangiectasia (HHT2) (#600376) 
Gonadotroph tumor; A482V mutation of unknown 
significance (D’Abronzo et al., 1999; J. Clin. Endocrinol. 
Metab. 84, 1716-1721) 
Germline 
 
ALK2/ ACVR1 
(#102576) 
Fibrodysplasia ossificans progressiva (FOP) (#135100) Germ line 
ALK3/ BMPR1A 
(#601299) 
Juvenile polyposis (#174900) 
Hereditary mixed polyposis (#610069) 
Juvenile polyposis of infancy (#612242) 
Germ line 
ALK4/ ACVR1B 
(#601300) 
Pancreatic carcinoma (#260350) Somatic  
ALK5/TGFBR1 
(#190181) 
Loeys-Dietz syndrome (#609192) 
Type 2 Marfan syndrome 
Germ line 
ALK6/BMPR1B 
(#603248) 
Frachydactyly (#112600) 
Fhondrodysplasia, acromesomelic, with genital anomalies 
(Demirhan et al., 2005; J. Med. Genet. 42, 314-317) 
Germ line 
TypeII receptors  
ACVR2/ ActRIIA 
(#102581) 
Human pituitary tumors (45%) (D'Abronzo et al., 1999; J. 
Clin. Endocrinol. Metab. 84, 1716-1721) 
Polymorphism 
ACVR2B/ ActRIIB 
(#602730) 
Left-right axis malformations, visceral heterotaxy 
(autosomal type 4) (HTX4) (#602730) 
Germ line 
BMPR2/BMPRII 
(#600799) 
Familial primary pulmonary hypertension (PAH) (#178600) Germ line 
TGFBR2/TBR2 
(#190182) 
Multiple cancers (colorectal, gastric, endometrial, prostate, 
breast, lung, hepatocellular, lymphoma, pancreatic,cervical, 
glioma) (#190182) 
Loeys-dietz syndrome (#610380) 
Atherosclerosis (McCaffrey, 2009; Front. Biosci. (Schol 
Ed). 1, 236-245) 
Marfan syndrome (#154700) 
Somatic / Germ 
line 
AMHR2/MISRII 
(#600956) 
Persistent Müllerian duct syndrome (#261550) Germ line 
Type III receptors 
Endoglin/CD105/ENG 
(#131195) 
Hereditary hemorrhagic telangiectasia (#187300) Germ line 
Betaglycan/ 
TGFBRIII (#600742) 
Possible association between gene expression levels of 
TGFBR3 and bone mineral density (#612728) 
Unknown 
Smads 
Smad2 
(#601366) 
Colorectal cancer (Takagi et al., 1998; Br. J. Cancer 78, 
1152-1155) 
Colon cancers (Takenoshita et al., 1998; Carcinogenesis 19, 
803-807) 
Somatic 
Smad3 
(#603109) 
Osteoarthritis (Yao et al., 2003; Eur. J. Hum. Genet. 11, 
714-717) 
Germline 
Smad4  
(#600993) 
Juvenile polyposis syndrome (#174900) 
Pancreatic, colorectal cancer (Schutte et al., 1999; Ann. 
Oncol. 10 Suppl 4, 56-59.) 
Germline 
Smad8 and Smad9 
(#603295) 
Primary pulmonary hypertension (#178600) Germline 
 Table 3. Selected clinical studies using agents targeting the TGF-β pathway 
Type of compounds Drug Target  Clinical Trial/Study (ClinicalTrials.gov 
Identifier) 
Human anti-TGF-β mAb 
(pan-neutralizing IgG4) 
GC1008 TGF-βs Phase I on malignant carcinoma, and renal cell 
carcinoma (NCT00356460) 
Phase II on Relapsed Malignant Pleural 
(NCT01112293) 
Phase I in treatment of Resistant Idiopathic Focal 
Segmental Glomerulosclerosis (NCT00464321) 
Human Anti-TGF-β1 
mAb 
CAT-192 TGF-β1 Phase I/II in Patients With Early Stage Diffuse 
Systemic Sclerosis (NCT00043706) 
TGF-β2 antisense ODN AP12009 
(Trabersden) 
TGF-β2 Phase I on pancreatic and Colorectal Neoplasms, 
and melanoma (NCT00844064) 
Phase II on Glioblastoma and Anaplastic 
Astrocytoma (NCT00431561) 
Phase III on Anaplastic Astrocytoma 
(NCT00761280) 
TGF-β2 antisense gene-
modified allogeneic 
tumor cell vaccine 
Lucanix TGF-β2 Phase III on Lung Neoplasm Carcinoma,  
Non-Small-Cell Lung: Stage IIIA (T3, N2 Only) 
Carcinoma, Non-Small-Cell Lung: Stage IIIB 
Carcinoma, Non-Small-Cell Lung: Stage IV 
(NCT00676507) 
Type I and II TGF-β 
receptors inhibitor  
LY21109761 TGFBR2 and 
ALK5  
Phase II on metastatic melanoma 
(NCT00383292) 
Peptide Inhibitor of 
TGF-β1 
P144 TGF-β1 Phase II for the treatment of Skin Fibrosis in 
Systemic Sclerosis (NCT00574613 and 
NCT00781053) 
 
Soluble Activin Type 
IIB Receptor 
AC-031 GD8/Myostatin 
 
Phase II Duchenne Muscular Dystrophy 
(NCT01099761) 
Phase I in healthy postmenopausal women with 
weight loss (NCT00952887) 
Human Anti-ALK1 mAb PF03446962 ALK1 Phase I on Advanced Solid Tumors 
(NCT00557856) 
Human/murine chimeric 
anti-endoglin mAb  
TRC105 Endoglin/CD105 Phase I on Cancer, Neoplasm Metastasis 
(NCT00582985) 
Human recombinant 
BMP2 
RhBMP2 BMP receptors Phase I of degenerative Lumbar Disc Disease, 
Spondylolisthesis and Spinal Stenosis 
(NCT00405600) 
Phase II to Degenerative Disc Disease 
(NCT00707265) 
Phase I of Osteoarthritis (NCT00243295) 
Phase II for Osteoporosis (NCT00752557) 
Human recombinant 
BMP7 
rhBMP7 BMP receptors Phase II for the treatment of Osteoarthritis of the 
Knee (NCT0111104) 
Human recombinant 
GDF5/BMP14 
rhGDF5/BMP14 BMP receptors Phase II the treatment of Degenerative Disc 
Disease (NCT00813813; NCT01124006) 
Phase I/II for the treatment of early Lumbar Disc 
Degeneration (NCT01158924) 
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